Clinical Trials Logo
  1. Home
  2. Choriocarcinoma
  3. NCT02664961

Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

Gestational Trophoblastic Neoplasia Clinical Trial

Official title:
A Phase 2A Study of TRC105 (With Option to Add Bevacizumab) in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

Clinical Trial Summary

The purpose of the study is to determine the overall response rate of single agent TRC105 and the combination of TRC105 and bevacizumab in patients with refractory GTN (including choriocarcinoma, placental site trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor (ETT)). Up to 30 patients will be treated.

Clinical Trial Description

TRC105 is a monoclonal antibody that binds to endoglin, an angiogenic target highly expressed on the tumor vessels and tumor cells in gestational trophoblastic neoplasia (GTN). Bevacizumab is a monoclonal antibody to vascular endothelial growth factor (VEGF) that inhibits angiogenesis and extends survival in patients with a wide variety of solid tumor types. TRC105 has been well tolerated as a single agent and when combined with bevacizumab. These antibodies may be efficacious in refractory GTN, a tumor type that is highly vascular and has been shown to densely express endoglin. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02664961
Study type Interventional
Source Tracon Pharmaceuticals Inc.
Contact
Status Terminated
Phase Phase 2
Start date March 2016
Completion date November 2018
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04562558 - Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia N/A
Not yet recruiting NCT06020755 - Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 7 Phase 2
Recruiting NCT06028672 - Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6 N/A
Withdrawn NCT05405192 - Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia Phase 2
Recruiting NCT03703271 - Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia Phase 3
Not yet recruiting NCT04303884 - Phase 2 Trial for Chemo-Resistant Gestational Trophoblastic Neoplasias With Pembrolizumab (CR-GTP) Phase 2
Recruiting NCT05139095 - Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia Phase 2
Recruiting NCT05635344 - A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia Phase 2
Recruiting NCT04756713 - Second Uterine Evacuation for Low-risk Gestational Trophoblastic Neoplasia Phase 3
Recruiting NCT03785574 - Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule N/A
Active, not recruiting NCT01823315 - Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia Phase 3
Not yet recruiting NCT06169644 - The Psychological Impact of GTN on Women Who Have Completed Chemotherapy Treatment
Recruiting NCT04812002 - Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy Phase 2